Published in J Nucl Med on November 22, 2016
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem (2004) 3.57
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev (2003) 2.78
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues. J Neurosci Methods (1983) 1.98
In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med (2007) 1.52
Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem (2007) 1.34
A new precursor for the radiosynthesis of [18F]FLT. Nucl Med Biol (2002) 1.15
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res (2008) 1.14
Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection. J Virol (2010) 1.13
Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nucl Med Biol (2010) 1.11
Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther (2009) 1.09
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics (2016) 1.02
In Vivo Labeling of Serum Albumin for PET. J Nucl Med (2014) 0.99
PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed Res Int (2014) 0.98
Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2. J Nucl Med (2012) 0.97
Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull (2013) 0.96
A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2008) 0.95
Binding properties of circulating Evans blue in rabbits as determined by disc electrophoresis. Atherosclerosis (1982) 0.94
New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem (2009) 0.93
DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med (2012) 0.90
Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol Pharm (2011) 0.87
Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis (2003) 0.85
Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB. J Nucl Med (2015) 0.85
Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. Nucl Med Biol (2015) 0.84
Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev (2016) 0.84
Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. Theranostics (2016) 0.79
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment. Bioconjug Chem (2015) 0.78
68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients. J Nucl Med (2015) 0.78